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ABSTRACT Epidemiological observations have linked increased host iron with ma-
laria susceptibility, and perturbed iron handling has been hypothesized to contribute
to the potentially life-threatening anemia that may accompany blood-stage malaria
infection. To improve our understanding of these relationships, we examined the
pathways involved in regulation of the master controller of iron metabolism, the
hormone hepcidin, in malaria infection. We show that hepcidin upregulation in Plas-
modium berghei murine malaria infection was accompanied by changes in expres-
sion of bone morphogenetic protein (BMP)/sons of mothers against decapentaplegic
(SMAD) pathway target genes, a key pathway involved in hepcidin regulation. We
therefore investigated known agonists of the BMP/SMAD pathway and found that
Bmp gene expression was not increased in infection. In contrast, activin B, which can
signal through the BMP/SMAD pathway and has been associated with increased
hepcidin during inﬂammation, was upregulated in the livers of Plasmodium berghei-
infected mice; hepatic activin B was also upregulated at peak parasitemia during in-
fection with Plasmodium chabaudi. Concentrations of the closely related protein ac-
tivin A increased in parallel with hepcidin in serum from malaria-naive volunteers
infected in controlled human malaria infection (CHMI) clinical trials. However, antibody-
mediated neutralization of activin activity during murine malaria infection did not af-
fect hepcidin expression, suggesting that these proteins do not stimulate hepcidin
upregulation directly. In conclusion, we present evidence that the BMP/SMAD signal-
ing pathway is perturbed in malaria infection but that activins, although raised in
malaria infection, may not have a critical role in hepcidin upregulation in this set-
ting.
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Malaria is one of the world’s deadliest and most geographically widespread humaninfectious diseases, causing hundreds of thousands of deaths per year (1). Malaria
infections contribute signiﬁcantly to the worldwide burden of anemia (2), and measures
taken to decrease malaria at the population level frequently decrease anemia preva-
lence (3).
The mechanisms involved in the pathogenesis of malarial anemia include increased
clearance of infected and uninfected red blood cells (iRBC and uRBC, respectively),
dyserythropoiesis as a consequence of cytokine upregulation, and inadequate absorp-
tion and utilization of iron, for which the iron-regulatory hormone hepcidin has been
implicated (reviewed in references 4–7). Hepcidin controls iron stores and localization
by causing internalization and degradation of the iron export protein ferroportin (8),
which mediates iron release into the circulation from erythrophagocytic macrophages
and across the basolateral membrane of enterocytes (9–11). Raised hepcidin therefore
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inhibits both recycling of red cell iron through macrophages and iron absorption from
the diet.
Hepcidin is upregulated during many bacterial, fungal, and viral infections (12–15)
and also during symptomatic and asymptomatic natural human malaria infections
(16–18), in volunteers undergoing controlled human malaria infection (CHMI) in clinical
trials (19), and in malaria-infected mice (20, 21). Raised hepcidin during asymptomatic
malaria infection is associated with poor iron absorption (22), and, in children with
postmalarial anemia, with diminished erythrocyte incorporation of orally administered
iron (23). Hepcidin renders mice infected with blood-stage malaria resistant to second-
ary sporozoite infection by decreasing the amount of iron in hepatocytes (20), and
hepcidin-mediated macrophage iron sequestration has been proposed as a mechanism
contributing to the increased growth of macrophage-tropic bacteria in malaria-infected
hosts (24).
Hepcidin levels increase homeostatically under high-iron conditions (7) and in
response to inﬂammation and infection (25) via the BMP/SMAD and interleukin-6
(IL-6)/STAT3 pathways, respectively. Appropriate regulation of hepcidin levels in re-
sponse to ﬂuctuations in iron is complex and requires many proteins, including Bmp6,
HJV, Bmp type I and type II receptors, Hfe, and TfR2. These molecules combine to sense
iron and to modulate transcription of hepcidin via the BMP/SMAD signaling pathway
(26). In contrast, during anemia and under conditions of erythroid demand, hepcidin
suppression occurs to facilitate iron release to plasma for erythropoiesis. A recently
identiﬁed bone marrow-derived erythropoietin-induced hormone named erythrofer-
rone likely plays a key role in hepcidin suppression in this context (27), which also
appears to act via BMP/SMAD signaling (28).
The SMAD pathway also may be involved in the hepcidin response to inﬂammation,
since the transforming growth factor  (TGF) superfamily member, activin B, is
upregulated by inﬂammation in mice, associating it with hepcidin upregulation, inde-
pendently of the IL-6 pathway (29). Activin B, a homodimer of two inhibin B subunits,
is known to be stimulated by inﬂammatory and infectious stimuli (30) and to contribute
to hepcidin upregulation in vitro (29). However, it is unclear whether activin B is an
essential component of the hepcidin response to inﬂammatory stimuli. One study
noted that hepcidin upregulation in response to LPS was preserved in activin B
knockout mice (Inhbb/) (31), suggesting that activin B is not required for hepcidin
upregulation in this context, while a second noted that the activin binding protein
follistatin blunted the hepcidin increase to lipopolysaccharide (LPS) in a murine model
(32). Additionally, the roles of related proteins activin A (a homodimer of two inhibin A
subunits) and activin AB (a heterodimer of inhibin B and inhibin A subunits) are less
deﬁned with regard to hepcidin upregulation, with some studies (33) showing that
activin A upregulates hepcidin but others demonstrating no effect of activin A or activin
AB (32, 34).
Here, we study molecular regulation of hepcidin expression in the context of murine
malaria infections and CHMI studies. We ﬁnd evidence that the BMP/SMAD pathway is
involved in hepcidin upregulation but that although activin B and activin A are
increased in malaria, these molecules are unlikely to play a major role in controlling
hepcidin expression.
RESULTS
Hepcidin upregulation during murine Plasmodium berghei infection is associ-
ated with increased BMP/SMAD pathway activity. We infected male BALB/c mice
with 103 P. berghei ANKA sporozoites and harvested tissues from infected and control
mice 2, 4, 6, or 8 days postinfection. Blood-stage parasitemia increased to 2 to 4% by
8 days postinfection (Fig. 1A). Hepatic hepcidin (Hamp1) mRNA expression was signif-
icantly increased on day 8 postinfection relative to day 2 (undetectable parasitemia)
(Fig. 1B), consistent with previous studies showing elevated hepcidin mRNA only when
parasitemia rises above a certain threshold (20, 21).
Spottiswoode et al. Infection and Immunity
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FIG 1 Hepcidin expression in Plasmodium berghei-infected BALB/c mice correlates with BMP pathway
indicator gene Id1, not inﬂammatory pathway indicators. Mice were infected with P. berghei ANKA
(Continued on next page)
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We then examined whether hepcidin expression was associated with the expression
of genes indicative of activity of two well-characterized hepcidin regulatory pathways:
the BMP/SMAD and IL-6/STAT3 pathways. We quantiﬁed hepatic expression of the
BMP-responsive gene, inhibitor of DNA-binding 1 (Id1) (35), and the IL-6/STAT3-
responsive acute-phase genes ﬁbrinogen alpha (Fga) (12) and serum amyloid alpha-1
(Saa-1). Id1 was signiﬁcantly upregulated on day 8 postinfection relative to days 2 and
4 (Fig. 1C) and associated positively with Hamp1 expression (Fig. 1D). This association
remained signiﬁcant when considering only the 9 mice from day 8 in the analysis (P 
0.05, r  0.68) (Fig. 1D, black symbols). We also analyzed hepatic expression of three
other BMP target genes, Atoh8, Smad6, and Smad7. Atoh8 expression correlated with
Hamp1 expression overall (see Fig. S1 in the supplemental material) and when analyses
were limited to day 8 (P 0.01, r 0.78); gene expression of Smad6 and Smad7 on day
8 also correlated with Hamp1 (P  0.01 for both, r  0.73 and 0.75, respectively),
although this correlation was not signiﬁcant when including the earlier time points with
lower parasitemia (Fig. S1).
Conversely, Fga expression was not increased on day 8 postinfection (Fig. 1E) and
did not correlate with hepcidin (Fig. 1F). Saa-1 increased on day 8 postinfection relative
to days 2 and 4 (Fig. 1G) but also was not signiﬁcantly correlated with hepcidin (Fig. 1H).
We used quantitative Western blot detection to measure phosphorylated STAT3
(pSTAT3) directly: pSTAT3 was not signiﬁcantly upregulated at day 8 postinfection
relative to any time points (Fig. 1I, blots from representative experiment shown in Fig.
S2) and did not correlate with hepcidin (Fig. 1J). When limiting analysis to day 8
samples (black symbols in all correlation graphs), there still was no signiﬁcant associ-
ation between Hamp1 and Fga, Hamp1 and Saa-1, or Hamp1 and pSTAT3. These data
suggest that in this blood-stage malaria model, increased BMP signaling parallels, and
so may contribute to, Hamp1 upregulation.
Expression of activin B, not Bmp genes, increases in P. berghei infection. Bmp6
knockout mice exhibit severe iron overload (36), and blocking Bmp6 in vivo also
decreases hepcidin and increases serum iron (37). However, we found that hepatic
Bmp6mRNA was downregulated as parasitemia increased (Fig. 2A). Other Bmp proteins
are capable of stimulating hepcidin transcription in vitro, and Bmp2 has recently been
shown to be a key hepatic regulator of hepcidin expression in vivo (38–41). We
therefore examined whether Bmp genes were upregulated in the liver, bone marrow,
and spleen samples. No signiﬁcant increases in Bmp6 (Fig. 2B) or Bmp2 (Fig. 2C) mRNA
were observed in any tissue on day 8 postinfection. Bmp9 mRNA was undetectable in
bone marrow and spleen and showed no increase on day 8 in the liver (Fig. 2D).
Therefore, hepcidin and Id1 upregulation during malaria infection was not accompa-
nied by changes in expression of Bmp genes.
Recent reports have provided evidence that increased hepatic activin B expression
during inﬂammation contributes to hepcidin induction, involving the BMP/SMAD path-
way (29, 32). Activin A, closely related to activin B, is increased in animal and human
sera following similar stimuli (30, 42). We found that hepatic activin B mRNA (Inhbb) was
increased signiﬁcantly on day 8 postinfection relative to days 2 and 4 (Fig. 2E), although
FIG 1 Legend (Continued)
sporozoites, and groups were sacriﬁced at 2-day intervals postinfection. Data in all graphs are combined
from 3 independent experiments (n  3 mice/day/experiment, n  9 total). (A) Mouse parasitemia as
percent infected red blood cells, monitored by thin smear. (B) Hamp1 mRNA in the liver increases on day
8 postinfection relative to day 2 (no parasitemia). BMP-responsive gene Id1 increases on day 8 postin-
fection (C) and correlates signiﬁcantly with hepcidin message (D). Acute-phase gene Fga message does
not increase on day 8 postinfection (E) and does not correlate with hepcidin (F). Acute-phase gene Saa-1
increases signiﬁcantly on day 8 postinfection (G) but does not correlate with hepcidin (H). STAT3
phosphorylation does not increase signiﬁcantly on day 8 postinfection (I) and does not correlate with
hepcidin (J). All genes are shown as normalized to endogenous control gene Hprt1. Statistical analyses
in dot plots are Dunn’s multiple-comparison tests after Kruskal-Wallis test. **, P 0.01; ***, P 0.001; ****,
P  0.0001. In all correlation graphs, each symbol denotes a single mouse, and the color of the symbol
indicates the day of sacriﬁce. All correlations are from Spearman’s correlation tests. P values and r values
are stated. ns, P  0.05.
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FIG 2 Bmp gene expression is not increased, but activin B (Inhbb) gene expression increases with hepcidin gene expression in
Plasmodium berghei-infected BALB/c mice. (A) Liver Bmp6 mRNA expression decreases on day 8 of infection (n  3 mice per day
(Continued on next page)
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activin A mRNA (Inhba) was signiﬁcantly decreased (Fig. 2F). Activin B expression
showed high intermouse variability but correlated signiﬁcantly with the BMP response
gene Id1 (Fig. 2H), although it did not show signiﬁcant correlation with Hamp1 (Fig. 2G).
Based on these results, we hypothesized that activin B contributes to hepcidin upregu-
lation in murine blood-stage malaria infection.
Activin B expression also increases at peak parasitemia during Plasmodium
chabaudi infection. To investigate whether these data were more broadly applicable,
we examined C57BL/6 mice infected with a second malaria parasite species, Plasmo-
dium chabaudi chabaudi AS (PccAS), widely used as a self-resolving model of severe
malarial anemia (43). In this experiment, C57BL/6 mice were injected intravenously with
105 PccAS-infected erythrocytes, and groups of mice were culled at intervals following
injection. Infected mice developed parasitemias that peaked around day 11 and then
resolved (Fig. 3A). Severe anemia, demonstrated by marked reductions in hemoglobin
concentration as parasitemia developed, reached a nadir concurrently with peak
parasitemia and persisted for a further week before returning to normal (Fig. 3B).
Regulation of hepcidin in this context is likely complicated due to conﬂicting signals
during the concurrent inﬂammation and anemia, which enhance and suppress hepcidin
expression, respectively. We did not observe increased liver Hamp1 mRNA expression
in the earlier phases of infection (Fig. 3C) despite evidence of inﬂammation (Fig. 3D,
increased Saa1), likely because of signals that suppress hepcidin arising as anemia
develops (for example, erythroferrone); indeed, as anemia becomes more severe,
Hamp1 expression is strongly decreased. Changes in activin gene expression similar to
those observed in P. berghei infection were observed during escalation of this para-
sitemia: there was a signiﬁcant upregulation of liver Inhbb mRNA expression at peak
parasitemia (Fig. 3E), with a concomitant smaller decrease in liver Inhba expression (Fig.
3F). Consistent with activin signaling, there was increased expression of Serpine1
(known to be induced by activin signaling) (Fig. 3G) as the parasitemia escalated to its
peak. Paralleling Hamp1 expression, hepatic Id1 was not upregulated in early infection
but was decreased as anemia became more severe (Fig. 3H), consistent with erythroid-
mediated suppression of hepcidin (as a result of anemia) requiring a decrease in Smad
signaling (28).
Hepcidin and activin A peptide are upregulated in human volunteers experi-
mentally infected with malaria. Given these observed changes in activin expression
in murine malaria infection, we sought to assess the applicability of our ﬁndings to
human infection. We measured serum concentrations of hepcidin, activin A, C-reactive
protein (CRP), and ferritin, besides transferrin saturation, in control subjects (n  18)
from three CHMI trials with P. falciparum. At the time of experimentation, we were
unable to obtain serum assays for activin B. Although in the murine model hepatic
activin A mRNA expression was suppressed at day 8, previous studies have suggested
that hepatic activin A mRNA does not associate with serum activin A concentrations
(30, 42).
Parasitemia data for each trial are shown Fig. S3A to C. Between trials, there were no
differences in times from challenge (C) to day of diagnosis (DoD), from C to the ﬁrst
quantiﬁable quantitative PCR (qPCR) measurement postinfection (termed PCR patency),
or in parasitemia measured by qPCR at DoD (Fig. S3D to F). In subsequent analyses, we
therefore combined data from the three trials to increase power.
Serum samples were taken 1 day prior to challenge (C1), at DoD, and 35 days
postinfection, when the infection had resolved (C35). Hepcidin concentrations were
FIG 2 Legend (Continued)
per experiment, n  9 total). (B to D) A representative experiment (n  3 mice per day) was examined further to see if other
Bmp genes increase in other candidate tissues. (B) Bmp6 mRNA did not show any trend toward upregulation in spleen or bone
marrow. (C) Bmp2 did not increase in liver, spleen, or bone marrow. (D) Bmp9 mRNA was undetectable in spleen and bone
marrow and did not increase in liver. Hepatic activin B message (Inhbb) is increased on day 8 postinfection (E), while hepatic
activin A mRNA (Inhba) is decreased (F). Inhbb expression shows a trend toward correlation with Hamp1 (G) and correlates with
Id1 (H). Statistical analyses in dot plots are Dunn’s multiple-comparison tests after Kruskal-Wallis test. *, P  0.05; **, P  0.01;
****, P  0.0001. All correlations are from Spearman’s correlation tests.
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FIG 3 Changes in activin gene expression during the course of Plasmodium chabaudi infection of C57BL/6 mice.
Groups of mice infected with PccAS were culled at intervals following infection (n  4/group). (A) Mouse
parasitemia as percent infected red blood cells (means  standard errors of the means [SEM]), monitored by thin
smear (ﬁlms were made from each mouse each day until they were culled, and data are plotted from day 6). (B)
Hemoglobin concentrations during PccAS infection (data are missing from one mouse on day 11 due to sample
clotting); C-d0 and C-d21 represent data from uninfected control mice culled on day 0 and day 21. (C to G) Hepatic
gene expression analysis by qRT-PCR, plotting expression relative to the endogenous control gene, Hprt1, yielding
the following results: no detectable increase in Hamp1 mRNA expression during parasitemia development but
marked suppression during severe PccAS-associated anemia (C); upregulation of the acute-phase response gene
Saa1 as parasitemia increases (D); increase in Inhbb mRNA expression on day 11 postinfection (E); downregulation
of Inhba around peak parasitemia (F); upregulation of activin-responsive gene Serpine1 around peak parasitemia
(G); BMP signaling indicator gene Id1 expression decreases at peak parasitemia (H). Statistical analyses were by
one-way ANOVA with Dunnett’s multiple-comparison test (relative to controls on day 0), and posttests were used.
*, P  0.05; **, P  0.01; ***, P  0.001. Plots depict means  standard deviations, except where y axes are plotted
on log scales, in which case statistical analyses are performed on log-transformed data and plots show geometric
means  geometric standard deviations.
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signiﬁcantly increased at DoD compared to those at both C1 and C35 (Fig. 4A).
Activin A showed a trend toward an increase on DoD over C1 and was signiﬁcantly
lower at the resolution of infection at C35 (Fig. 4B). CRP (Fig. 4C) and ferritin (Fig. 4D)
were elevated at DoD. Accordingly, transferrin saturation was decreased at DoD
compared to that at C1, indicative of inﬂammatory hypoferremia (Fig. 4E).
A strong correlation was evident between Δ hepcidin and Δ activin A protein in
infection (where Δ is the value at DoD minus the average of values at C1 and C35).
Those volunteers who demonstrated the most pronounced hepcidin increases at DoD
also showed the greatest activin A increases (Fig. 4F). Full data for each volunteer are
shown in Fig. S4.
In two published studies that compared activin A tissue mRNA levels with circulating
protein, one tested only liver and the other examined multiple tissues, including spleen
FIG 4 Changes in serum hepcidin, activin A C-reactive protein (CRP), ferritin, and transferrin saturation
during CHMI trials. (A) Serum hepcidin increased on DoD compared to that at either the C1 or C35
time point. Hepcidin was measured in n  18 volunteers. (B) Activin A was signiﬁcantly upregulated at
DoD versus the level at C35. CRP (C) and ferritin (D) increased at DoD over other time points. (E)
Transferrin saturation was reduced on DoD compared to that at C1 only. (F) Δ serum hepcidin and Δ
activin A were signiﬁcantly correlated (Spearman’s correlation test); each symbol denotes a single
individual. Δ protein increases during infection were calculated by the value at DoD minus the mean of
values at C1 and C35. Data were missing for iron and activin A measurements due to insufﬁcient
sample volume available (n  17 in panels C, D, and E and n  16 in panels B and F). (A to E) All data
are log transformed, and statistical analyses are on log-transformed data. Statistical comparisons in
before-after dot plots are Dunnett’s multiple-comparison tests after ANOVA test. Spearman correlation is
shown in panel F, and data are not log transformed. *, P  0.05; **, P  0.01; ***, P  0.001.
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December 2017 Volume 85 Issue 12 e00191-17 iai.asm.org 8
 o
n
 N
ovem
ber 27, 2017 by KB, Københavns Universitetsbibliotek
http://iai.asm
.org/
D
ow
nloaded from
 
and bone marrow; neither found signiﬁcant correlations (30, 42). Further work has
suggested that stored activin A protein can be produced and released into the
circulation by hematopoietic cells, and activin A can also be produced de novo from
circulating white blood cells (44, 45). We previously demonstrated that hepcidin mRNA
was upregulated in peripheral blood mononuclear cells (PBMC) from healthy malaria-
naive donors cocultured with P. falciparum iRBC (46). We quantiﬁed activin A mRNA
(INHBA) on samples from four donors from this study and found that both hepcidin
(HAMP) and activin A mRNA were signiﬁcantly upregulated in PBMC cocultured with
iRBC but not uRBC (Fig. S5A and B). Thus, serum activin A induction during malaria
infection may at least in part be produced by PBMC exposed to iRBC.
Activin proteins upregulate hepcidin. Previous studies have demonstrated hep-
cidin induction by recombinant activin B protein in primary hepatocytes or hepatoma
cell lines (29, 32). Likewise, we found that activin B and, to a lesser extent, activin A,
induced HAMP mRNA in HepG2 hepatoma cells at 4 h posttreatment (Fig. S6A) but did
not signiﬁcantly induce ID1 mRNA (Fig. S6B). Hepcidin induction by both activin
proteins was most pronounced between 1 and 8 h posttreatment (Fig. S6C and D).
Pretreatment of HepG2 cells with the BMP type 1 receptor inhibitor molecule LDN-
193189 (LDN) (47) prior to activin administration reduced the basal expression of both
HAMP (Fig. S6E) and ID1 (Fig. S6F) but did not decrease the proportional increase in
response to activin treatment. These data are consistent with recent reports suggesting
that activin A/B-mediated hepcidin upregulation proteins occur through the LDN-
sensitive BMP type 1 receptor Alk2 or Alk3 (29, 32), but that this pathway is resistant to
LDN inhibition as a result of Alk2 complex formation with ActRIIA (34).
Anti-activin A/B antibodies do not decrease hepcidin expression in a malaria-
infected mouse model. We ﬁnally investigated whether inhibiting activin activity
affected hepcidin expression during murine blood-stage P. berghei infection.
Sporozoite-infected mice were treated with anti-activin A/B or isotype control antibod-
ies on days 6 and 7 postinfection (30 and 6 h prior to sacriﬁce on day 8, respectively).
Expression of Serpine1 (encoding plasminogen activator inhibitor 1 [PAI-1]), which is
responsive to activins (48) and the activin-regulatory gene encoding follistatin (Fst),
were suppressed in mice treated with anti-activin antibodies, indicative of effective
inhibition of liver activin signaling (Fig. 5A and B). However, Hamp1 (Fig. 5C) and Id1
expression (Fig. 5D) were not signiﬁcantly different between malaria-infected mice
treated with anti-activin A/B and isotype control antibodies. There was no difference in
parasitemia between the two groups (Fig. 5E).
DISCUSSION
Iron is required for Plasmodium growth, and host iron-handling proteins can inﬂu-
ence outcome of infection; for example, lipocalin-2, which can sequester iron, controls
the severity of Plasmodium yoelii infection in mice (49). Here, we focused on regulation
of the iron-regulatory hormone hepcidin during malaria. Hepcidin is raised in uncom-
plicated malaria infection in mice and humans (18–20). Hepcidin redistributes iron into
the macrophage compartment and away from the serum and so may contribute to
dyserythropoiesis and the development of malarial anemia. In established severe
malarial anemia, hepcidin then is suppressed (50) through a pathway that likely
involves the erythroid progenitor-derived factor erythroferrone (51). The initial hepcidin
upregulation blocks oral iron absorption during and after infection (22, 23) and plays a
role in determining host susceptibility to malaria superinfection (20) and, possibly,
coinfections with other pathogens (24). Understanding the mechanisms of hepcidin
induction during uncomplicated malaria therefore is important.
IL-6 upregulates hepcidin and this cytokine increases in malaria infection, and in
some studies, IL-6 has been correlated with hepcidin in human serum (50, 52, 53);
however, in one study of infected children, urinary IL-6 and hepcidin were not associ-
ated (16). Murine studies have also shown different outcomes: one study found a close
correlation between pSTAT3 levels and Hamp1 (21), but another noted only minor IL-6
upregulation, without pSTAT3 increase, in infected mice (51). Hepcidin induction in
Activins and Hepcidin Regulation in Malaria Infection Infection and Immunity
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primary hepatocytes treated with serum from infected mice was shown to be abro-
gated by the BMP pathway inhibitor dorsomorphin, while IL-6 neutralizing antibodies
were less effective (20). Finally, PBMC, when cocultured with P. falciparum-infected red
blood cells, upregulated hepcidin expression without appreciable IL-6 increases (46).
The role of IL-6 in hepcidin upregulation in malaria infection is unclear.
FIG 5 Hepcidin expression in murine P. berghei infection was not decreased by administration of anti-
activin A and anti-activin B antibodies. Mice were infected with P. berghei ANKA sporozoites as described
in the text and sacriﬁced at day 8 postinfection. Mice were injected i.p. twice with a cocktail of anti-activin
A and anti-activin B antibodies (containing 100 g of each, in 400 l) at 6 and 30 h prior to sacriﬁce; controls
were given isotype IgG control (200 g, in 400 l) only. Data in all graphs are combined from 2
independent experiments (n  6 mice per treatment per experiment, n  12 total). Gene expression is
shown relative to housekeeping gene Hprt1. mRNA of activin-responsive genes Serpine1 (A) and Fst
(follistatin) (B) were signiﬁcantly decreased in anti-activin treated mice, indicating antibody efﬁcacy. Hamp1
(C) and Id1 (D) mRNA were not signiﬁcantly altered between infected mice treated with anti-activin A/B and
isotype IgG control. (E) Parasitemia on day 8 (day of sacriﬁce) was unchanged between groups. Statistical
analyses are Mann-Whitney tests. ****, P  0.0001.
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During blood-stage P. berghei ANKA malaria infection in mice, we found that
hepcidin expression correlated most closely with hepatic expression of the BMP/SMAD
response genes Id1 and Atoh8 and less so with IL-6/STAT3 pathway response gene Fga
or Saa-1 or STAT3 phosphorylation. These ﬁndings indicate that hepcidin upregulation
in this model co-occurs with BMP/SMAD pathway signaling. The expression of Bmp
genes in infected mice was unchanged or moderately downregulated as parasitemia
increased. Of relevance, previous work demonstrated that Bmp gene expression was
not elevated in mice injected with LPS despite evidence of BMP/SMAD pathway activity
occurring concurrently with Hamp1 elevation (29). Hepatic activin B mRNA (Inhbb) was
signiﬁcantly raised post-LPS injection, suggesting that activins play a role in hepcidin
upregulation through the BMP/SMAD pathway in inﬂammatory contexts (29, 30, 34). A
previous study noted a marginal increase in hepatic message levels of activin B, and a
decrease in Bmp6, in a murine model of malaria infection (51).
Activin proteins were initially discovered as reproductive factors, but increasing
evidence has demonstrated a role in the acute host response to infectious and
inﬂammatory stimuli, as well as shaping the subsequent immune response (54). Activin
A increases in serum of septic human patients (55, 56) and in animals following LPS
injection (30, 34, 42, 57). Notably, although activin A protein levels increase in sera
post-LPS injection, hepatic expression of Inhba mRNA decreases (30, 42). This discon-
nect between activin A serum protein and liver expression have led researchers to
hypothesize that activin A is at least partially regulated at the posttranscriptional level
and/or produced by tissues other than the liver, such as bone marrow-derived cells (42,
58), peripheral blood monocytes (45), or dendritic cells (44). Activin B previously has
been thought to be functionally similar to activin A, possibly with slightly weaker
effects (59–61), although studies of knockout mice have identiﬁed some differences in
the roles of the two proteins (62–64). The effect of activin A and activin B on hepcidin
regulation has been debated (32–34). In our in vitro system, we found some effects of
activin A on hepcidin upregulation, although it was less potent than activin B.
We found increased hepatic Inhbb expression in P. berghei-infected mice, occurring
concurrently with hepcidin and Id1 expression increase. Hepatic activin A (Inhba) mRNA
was decreased (as described in reference 29) as Hamp1, Inhbb, and parasitemia in-
creased. Similarly, increased hepatic Inhbb expression and decreased Inhba expression
were observed during the peak parasitemia of Plasmodium chabaudi infection of
C57BL/6 mice, together with upregulation of Serpine1 (consistent with activin signal-
ing).
Importantly, an increase in Inhbb expression does not formally indicate an increase
in activin B protein, as activin B subunits can also combine with activin A subunits
to form activin AB protein. However, given the message decrease in Inhba in the liver,
decreasing the local concentration of activin A subunits, it is likely that the Inhbb
increase we observed did result in an increase in circulating activin B and not activin AB.
An enzyme-linked immunosorbent assay (ELISA) for human activin B protein has
been reported (65) but was not available at the time of experimentation. However,
given the known independence of activin A liver mRNA and serum protein levels in
animal models (30, 42), a possible role of activin A in hepcidin upregulation, and several
studies that indicate that serum levels of activin A and B are coupregulated in different
inﬂammatory and infectious states (66–68), we next chose to extend our studies by
quantifying serum activin A and hepcidin concentrations from humans infected with P.
falciparum as part of CHMI clinical trials. We found that hepcidin was increased during
untreated blood-stage parasite infection. A previous CHMI study also reported in-
creased hepcidin (19), although importantly this prior study only noted hepcidin
increases subsequent to the initiation of antimalarial treatment, which likely induces
transient inﬂammation due to release of parasite-derived material into the blood-
stream. The increase in hepcidin we observed was accompanied by increases in
acute-phase markers, decreased transferrin saturation, and increased serum activin A.
Moreover, changes in activin A and hepcidin during infection were correlated, with the
volunteers who exhibited the greatest hepcidin induction also demonstrating the most
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marked increases in activin A concentration. To our knowledge, this is the ﬁrst report
of activin A induction in the context of malaria infection and also the ﬁrst to directly
compare hepcidin and activin A levels in human serum. The moderate response we
observed in volunteers infected in CHMI trials may be more pronounced in naturally
infected individuals in the ﬁeld, in whom parasitemia levels can greatly exceed the low
parasitemia that is allowed in CHMI. We also showed that human PBMC, when cocul-
tured with iRBC, upregulated activin A mRNA, providing one plausible physiological
source for increased activin A serum levels during infection.
Finally, we treated P. berghei-infected mice with a combination of anti-activin A and
anti-activin B antibodies to test whether activin neutralization could abrogate the
hepcidin response. The antibody treatment was efﬁcacious in blocking activin signal-
ing, as shown by signiﬁcant decreases in activin-regulated genes Serpine1 and Fst, but
there was no observed change in hepcidin or Id1 expression. These data suggest
activins are not required for hepcidin upregulation in this murine model of Plasmodium
infection, although they do not rule out that activins could play a role in hepcidin
regulation in malaria in humans. Our ﬁndings are consistent with a recent study
demonstrating that Inhbb/ mice continued to display hepcidin upregulation in
response to LPS challenge (31) but contrast with another study that demonstrated
abrogation of hepcidin upregulation after LPS challenge by use of the activin-binding
protein follistatin (32).
In conclusion, we provide evidence that hepcidin upregulation in uncomplicated
blood-stage Plasmodium infection is correlated with BMP/SMAD pathway activity in the
liver. However, despite showing perturbations to expression of activins A and B in
mouse and human malaria and conﬁrming that activins induce hepcidin expression,
neutralization of activins during murine malaria infection did not affect hepcidin. This
suggests other factors are responsible for hepcidin expression in this context.
MATERIALS AND METHODS
Plasmodium berghei sporozoite infections of BALB/c mice. Six- to 8-week-old male BALB/c mice
(Harlan, United Kingdom) were housed under speciﬁc-pathogen-free conditions with ad libitum access to
standard chow (2018SX; Fe2 content of 200 ppm; Harlan-Teklad). Mice were infected intravenously
(i.v.; via tail vein) with 103 Plasmodium berghei ANKA sporozoites (obtained from Anopheles stephensi
mosquito salivary glands 21 days after feeding on blood containing infectious gametocytes) in 200 l
RPMI as previously described (69). Control mice were injected with 200 l RPMI i.v. Mice were culled and
samples harvested at 2, 4, 6, or 8 days postinfection. For activin neutralization experiments, mice were
injected intraperitoneally (i.p.) on days 7 and 8 postinfection (30 h and 6 h prior to culling, respectively)
with 100 g each of anti-activin A (MAB3381; Bio-Techne, Abingdon, United Kingdom) and anti-activin
B (MAB659; Bio-Techne) antibodies, or 200 g isotype control IgG1 (MAB002; Bio-Techne), in 400 l
Dulbecco’s phosphate-buffered saline (PBS) (Gibco) vehicle.
Plasmodium chabaudi infections of C57BL/6 mice. Six-week-old female C57BL/6 mice were
infected intravenously with 105 Plasmodium chabaudi chabaudi AS (PccAS)-infected red blood cells in
Krebs glucose solution (PBS plus 1% glucose), harvested during the escalation of parasitemia from donor
C57BL/6 mice infected from a frozen parasite stock (serially blood passaged rather than recently
mosquito transmitted). Groups of 4 mice were culled at days 3, 8, 11, 14, 17, and 21 postinfection; 2
groups of 4 uninfected mice were culled as controls on day 0 and day 21. Parasitemia was assessed by
counting Giemsa-stained thin ﬁlms.
Mouse sample harvest and storage. Mice were given a lethal anesthetic injection and blood was
extracted via cardiac puncture; serum was isolated using BD SST Microtainers (Bunzl Healthcare, London,
United Kingdom), and spleens, livers, and right hind legs were collected. For Plasmodium chabaudi
infections, blood was also taken into BD EDTA Microtainers for assessment of anemia.
Livers and spleen explants (approximately 2 mm3) were preserved in RNAlater (Qiagen, Crawley,
United Kingdom) for RNA extraction. Liver was snap-frozen in liquid nitrogen for Western blot analysis.
Bone marrow was aspirated from tibias and immediately lysed in 350 l RLT buffer (Qiagen), homoge-
nized using QIAshredders (Qiagen), and stored at 20°C for later RNA extraction.
Mouse serum iron measurements. Serum iron and unsaturated iron binding capacity (UIBC) of
mouse sera were measured using the iron/total iron binding capacity (TIBC) reagent set (Pointe
Scientiﬁc), scaling the recommended protocol to 96-well-plate format (6% volume) and reading absor-
bances (560 nm) on an Inﬁnite M200 Pro Tecan microplate reader. TIBC was calculated as serum iron plus
UIBC. Transferrin saturation (percent) was calculated by serum iron divided by TIBC times 100.
Measurement of hemoglobin concentrations in mice. Hemoglobin concentrations were measured
in EDTA-blood using an ABX Pentra60 benchtop analyzer (Horiba).
Hepatoma cell culture and activin protein treatment. All in vitro experiments were performed
in biological duplicate. HepG2 human hepatoma cells (ECACC) were cultured in minimal essential
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medium (MEM-alpha modiﬁcation; Sigma) supplemented with 10% fetal calf serum (FCS; PAA
Laboratories), 2 mM glutamine, 100 U/ml penicillin, and 0.1 mg/ml streptomycin (all Sigma). Cells
were plated in a 12-well plate at 2 	 105 cells/ml, 1 ml/well, allowed to adhere overnight, and
starved for 5 h in MEM-alpha with 0.1% FCS prior to activin treatment. Cells were treated with
recombinant activin A (50 ng/ml), activin B (50 ng/ml), or BMP9 (100 ng/ml; all Bio-Techne) for 4 h
unless otherwise stated. LDN-193189 (LDN; 100 nM; Axon Medchem), when used, was added 30 min
before administration of activins/BMP9.
Human PBMC culture and treatment. PBMC had been isolated using a Ficoll (GE Healthcare)
gradient from the heparinized blood of consenting healthy adult donors according to the Weatherall
Institute of Molecular Medicine local procedures, as described previously (12, 46). Cells (5 	 106 cells/ml,
1 ml/well, 12-well plate) plated in RPMI 1640 media (10% FCS supplemented with 2 mM glutamine, 100
U/ml penicillin, and 0.1 mg/ml streptomycin; all Sigma) were cocultured with 107 P. falciparum A4 strain
schizont iRBC or an equivalent number of control uRBC for 3 h as previously reported (46). Gene
expression data from these experiments previously were published elsewhere (46); here, we investigated
changes in activin expression in the same samples.
RNA extraction, cDNA synthesis, and quantitative real-time PCR (qRT-PCR). RNA was extracted
using RNeasy minikits (Qiagen) according to the manufacturer’s protocol. Mouse spleen and liver
samples from RNAlater were homogenized using a TissueRuptor (Qiagen). Cells cultured in vitro were
homogenized using QIAshredders (Qiagen).
RNA concentrations were quantiﬁed using a NanoDrop ND-1000 spectrophotometer (Wilmington,
DE, USA). cDNA was synthesized using the high-capacity RNA-to-cDNA kit (Applied Biosystems). Gene
expression was quantiﬁed relative to endogenous control genes by qRT-PCR using TaqMan gene
expression master mix and inventoried TaqMan assays (all Applied Biosystems) in 10-l reaction mixtures
in technical duplicate on a 7500Fast or QuantStudio7 instrument (Applied Biosystems), as previously
described (12). Details of the inventoried TaqMan gene expression assays used are shown in Fig. S7 in
the supplemental material.
Western blotting. Approximately 10-mg frozen murine liver explants were lysed on wet ice using
a TissueRuptor in lysis buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 5 mM EDTA, pH 8, 1% NP-40, and
inhibitors of proteases and phosphatases [all Sigma]) as in previous studies (70). Protein concentration
was assessed using the Thermo Scientiﬁc Pierce protein assay (Fischer Scientiﬁc); lysates were diluted to
20 g protein/10 l solution with 1/3-volume bromophenol blue loading buffer, run through 12% SDS
separating gel, and blotted onto activated polyvinylidene diﬂuoride (PVDF) membranes. Size comparison
was provided by a Bio-Rad Precision Plus Protein all blue ladder (Bio-Rad).
Membranes were blocked in Odyssey blocking buffer (LI-COR Biosciences) for 1 h and incubated
overnight with a combination of two primary antibodies: mouse anti--actin (1:10,000; antibody AC15;
Sigma-Aldrich) and either rabbit anti-phosphorylated STAT3 (pSTAT3; 1:1,000; D3A7; Cell Signaling) or
rabbit anti-STAT3 (1:3,000; 79D7; Cell Signaling). Membranes were washed 3	 in PBS–Tween (0.1%) and
then incubated for 1 h with two secondary antibodies (donkey anti-mouse red 680 [1:20,000] and goat
anti-rabbit green 800 [1:15,000]; LI-COR Biosciences) in 50% Odyssey–50% PBS buffer with 0.01% SDS and
0.1% Tween. Membranes were washed 3	 in PBS–Tween (0.1%) and 1	 in PBS only and then dried prior
to examination with a LI-COR Biosciences instrument. Band intensities were quantiﬁed using LI-COR
software. Each pSTAT3 or STAT3 band was normalized to its internal -actin control prior to comparison
with the mean of normalized band intensities of 3 uninfected age- and sex-matched mice sacriﬁced
simultaneously and run on the same gel.
CHMI studies. Serum samples were obtained from eighteen 18- to 50-year-old, malaria-naive,
unvaccinated volunteers from three separate United Kingdom CHMI clinical trials conducted to
assess the efﬁcacy of novel vaccines: NCT01623557, NCT00890760, and NCT01142765 (also termed
VAC045, MAL034B, and VAC039, respectively), all registered with ClinicalTrials.gov (71–73). All
volunteers gave written informed consent to participate and for their samples to be stored and used
for further investigations to assess immunity to malaria. The samples analyzed presently were from
the six nonvaccinated volunteers who formed the infectivity control group in each of the three CHMI
studies.
As detailed elsewhere (71), ﬁve Anopheles stephensimosquitoes infected with P. falciparum 3D7 clone
sporozoites were allowed to bite each volunteer. The day of infection is termed the day of challenge (C).
From day 6.5 postchallenge until 21 days postchallenge, volunteers were assessed once to twice daily by
Giemsa-stained thick smear for the presence of parasites, and samples were collected for qRT-PCR
analysis of P. falciparum parasitemia. Upon meeting the criteria for diagnosis (71–73), treatment with
artemether-lumefantrine (Riamet) or atovaquone-proguanil (Malarone) was initiated. This time point was
termed day of diagnosis (DoD) and also was typically the point of maximal parasitemia. Larger blood
samples were collected the day before CHMI (C1), at DoD, and after resolution of infection (C35), and
as such samples from these time points were available for investigation here.
Measurement of human serum analytes. Serum iron, UIBC, CRP, and ferritin in human samples
were measured using an Abbott Architect cSystem Analyzer as described previously (14). TIBC and
transferrin saturation were calculated as described above.
Serum hepcidin was quantiﬁed using the hepcidin-25 (human) enzyme immunoassay kit (EIA;
Bachem), with the protocol modiﬁed as previously described (14, 74). Samples were initially measured at
1:8 dilution. Concentrations were determined using a 2-fold dilution curve (25 ng/ml to 0.05 ng/ml) as
previously described (14). Duplicate concentrations with coefﬁcients of variation of 15% were rerun.
Samples with hepcidin concentrations falling outside the linear portion of the standard curve were rerun
at appropriate dilutions. For those in which hepcidin was not detectable at the lowest possible dilution
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(typically 1:1), a value of 50% of the limit of detection (LOD; 0.118 ng/ml), multiplied by the dilution at
which they were run, was assigned.
Serum activin A levels were measured by solid-phase sandwich ELISA (R&D Systems). Samples and
standards were run in duplicate; samples with high coefﬁcients of variation (15%) were rerun.
Statistical analysis. Data processing was performed using Microsoft Excel. Statistical analyses were
performed and graphs generated using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA). All
analyses on untransformed data were nonparametric. In mouse experiments, Kruskal-Wallis tests with
Dunn’s multiple-comparison posttests were used to speciﬁcally compare the group of interest with the
others. In experiments with only two groups, Mann-Whitney tests were used. In human data with paired
samples, data were log transformed and analysis of variance (ANOVA) with Dunnett’s multiple-
comparison tests were used. In grouped analyses shown in Fig. S5, ANOVA was used. All correlations are
Spearman’s correlations. The signiﬁcance level was set at P  0.05 throughout.
Ethics. All murine malaria infection experiments were performed in accordance with the terms of the
United Kingdom Animals (Scientiﬁc Procedures) Act Project License (PPL 30/2889) and were approved by
the University of Oxford Animal Welfare and Ethical Review Body.
All human CHMI trials were conducted in accordance with good clinical practices (GCP) and the
principles of the Declaration of Helsinki. Trials were approved by the Oxfordshire Research Ethics
Committee. The results of each trial and details of all necessary ethical and regulatory approvals for CHMI
trials are reported elsewhere (71–73).
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